Predischarge Prediction of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Derivation and Validation of a Risk Prediction Score

BACKGROUND: Ninety-day hospital readmission rates following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) range from 20 to 40%. OBJECTIVE: The aim of this study was to develop and validate a simple score to predict readmissions following CRS/HIPEC. STUDY DESIGN: Usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rieser, Caroline J., Hall, Lauren B., Kang, Eliza, Zureikat, Amer H., Holtzman, Matthew P., Pingpank, James F., Bartlett, David L., Choudry, M. Haroon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Peritoneal Surface Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349345/
https://www.ncbi.nlm.nih.gov/pubmed/33486643
http://dx.doi.org/10.1245/s10434-020-09547-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349345/
https://www.ncbi.nlm.nih.gov/pubmed/33486643
http://dx.doi.org/10.1245/s10434-020-09547-7

Ejemplares similares